3- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dione

01/01/2021 - "Herein, a population pharmacokinetic (popPK) model of CC-122 was developed and the influence of demographic and disease-related covariates on population pharmacokinetic parameters was assessed based on data from three clinical studies of CC-122 (dose range, 0.5-15 mg) in healthy subjects and cancer patients. "
01/01/2021 - "Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies."
01/01/2019 - "A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies."
10/01/2023 - "Avadomide showed anti-tumor effects in human PDAC cell lines. "
01/01/2021 - "This phase I multicenter study evaluated avadomide in Japanese patients with advanced solid tumors or NHL. "

01/01/2016 - "In the three patients included in a phase I clinical trial (NCT01421524), we report the immunomodulatory effects and efficacy of CC-122, a novel pleiotropic pathway modifier compound originally developed for broad diffuse large B-cell lymphoma (DLBCL). "
01/01/2016 - "CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma."
08/06/2015 - "In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of diffuse large B-cell lymphoma (DLBCL)."
08/06/2015 - "Here we report that CC-122, a new chemical entity termed pleiotropic pathway modifier, binds CRBN and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo, and in patients, resulting in both cell autonomous as well as immunostimulatory effects. "
01/01/2021 - "CC-122 is a next-generation cereblon E3 ligase-modulating agent that has demonstrated promising clinical efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). "

10/01/2020 - "CC-122 as monotherapy and in combination with other agents is being evaluated for multiple indications including hematologic malignancies and advanced solid tumors. "
12/01/2019 - "Avadomide has multiple pharmacologic activities including potent immune modulation, antiangiogenic, antitumor, and antiproliferative activity and is being evaluated as an oncology treatment for hematologic malignancies and advanced solid tumors. "
01/01/2016 - "CC-122 is being developed as an oncology treatment for hematologic malignancies and advanced solid tumors. "
01/01/2021 - "Our findings suggest that patients with hematologic malignancies harboring these ZMYM2 fusion proteins may benefit from avadomide treatment."
01/01/2021 - "Here, we found that avadomide (CC-122) induces CRBN-dependent ubiquitination and proteasomal degradation of ZMYM2 (ZNF198), a transcription factor involved in balanced chromosomal rearrangements with FGFR1 and FLT3 in aggressive forms of hematologic malignancies. "

01/14/2022 - "Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies."
01/01/2021 - "Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. "
01/01/2021 - "Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies."
01/01/2021 - "Model utility was demonstrated by simulating the avadomide effect in the virtual population for various dosing schedules and determining the incidence of high-grade neutropenia, its duration, and the probability of recovery to low-grade neutropenia."
01/01/2021 - "The neutropenia model was integrated with avadomide-specific pharmacokinetic and pharmacodynamic models to capture dose-dependent effects. "

02/05/2023 - "Studies further confirmed that several derivatives which exhibit strong anti-proliferation effect induce the significant degradation of IKZF1/3. In addition, we found that the best compound 14 (SIAIS355035) exhibits better degradation activity and better anti-proliferation activities than CC-122, especially in diffuse large B lymphoma cell lines. "
01/01/2020 - "This phase 1 dose-expansion study assessed safety and clinical activity of avadomide monotherapy in patients with de novo R/R DLBCL and transformed lymphoma. "
01/01/2020 - "Ninety-seven patients with R/R DLBCL, including 12 patients with transformed lymphoma, received 3 to 5 mg avadomide administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal. "
01/01/2016 - "CC-122 has multiple activities including modulation of immune cells, antiproliferative activity of multiple myeloma and lymphoma cells, and antiangiogenic activity. "